Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.51 |
| ▸ | VEGFA | P15692 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 7/20 | 0.49 |
| ▸ | MMP9 | P14780 | 7/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.43 |
| ▸ | IL1RN | P18510 | 2/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645984 | 0.79 | EGLN1 (0.56) | EGLN1VEGFAMMP2MMP9ERAP2 | |
| SCHEMBL10301532 | 0.78 | EGLN1 (0.45) | EGLN1VEGFAMMP2MMP9ERAP2 | |
| SCHEMBL31165783 | 0.78 | SMN1; SMN2 (0.42) | TSHRSMN1; SMN2HSD17B10TDP1L3MBTL1 | |
| SCHEMBL15804040 | 0.78 | ELANE (0.46) | TSHRSMN1; SMN2HSD17B10TDP1L3MBTL1 | |
| SCHEMBL10465376 | 0.77 | EGLN1 (0.54) | EGLN1VEGFAMMP2MMP9ERAP2 | |
| SCHEMBL9453904 | 0.77 | EGLN1 (0.54) | EGLN1VEGFAMMP2MMP9ERAP2 | |
| SCHEMBL9453861 | 0.76 | EGLN1 (0.53) | EGLN1VEGFAMMP2MMP9ERAP2 | |
| SCHEMBL13036960 | 0.74 | EGLN1 (0.51) | EGLN1VEGFAMMP2MMP9ERAP2 | |
| SCHEMBL24067445 | 0.74 | EGLN1 (0.51) | EGLN1VEGFAMMP2MMP9ERAP2 | |
| SCHEMBL13448510 | 0.74 | MAPT (0.49) | TSHRSMN1; SMN2HSD17B10TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | EGLN1 3461/4885VEGFA 4867/4885MMP2 3367/4885 |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | EGLN1 3461/4885VEGFA 4867/4885MMP2 3367/4885 |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | EGLN1 3461/4885VEGFA 4867/4885MMP2 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.